Albireo Pharma, Inc.

NasdaqCM:ALBO 株式レポート

時価総額：US$921.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Albireo Pharma マネジメント

マネジメント 基準チェック /24

主要情報

Ron Cooper

最高経営責任者

US$6.0m

報酬総額

CEO給与比率9.8%
CEO在任期間7.7yrs
CEOの所有権0.2%
経営陣の平均在職期間4.2yrs
取締役会の平均在任期間5.5yrs

経営陣の近況

Recent updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Oct 11

Albireo Pharma: Assessing The Sagard Deal

Oct 03

Albireo gains on royalty agreement for pruritus therapy

Sep 22

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

Sep 06

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Aug 23
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Aug 15

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Jul 22

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

May 10
Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

Albireo: A Speculative Play With Upside

May 03

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Feb 02
Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Jan 31

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Nov 24

Albireo Pharma: A Post Approval Assessment

Aug 09

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Jun 21

Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Jun 11
Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat

Apr 26

Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Feb 27
Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Albireo launches late-stage trial of odevixibat in Alagille Syndrome

Dec 17

Albireo submits U.S. and European applications for odevixibat in liver disease

Dec 09

Albireo Pharma (ALBO) Investor Presentation - Slideshow

Nov 17

Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease

Nov 13

CEO報酬分析

Albireo Pharma の収益と比較して、Ron Cooper の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$6mUS$590k

-US$34m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$136m

Mar 31 2021n/an/a

-US$120m

Dec 31 2020US$3mUS$570k

-US$108m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$3mUS$551k

-US$63m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$63m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$4mUS$530k

-US$46m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$28m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$2mUS$460k

-US$24m

Sep 30 2017n/an/a

-US$31m

Jun 30 2017n/an/a

-US$28m

Mar 31 2017n/an/a

-US$20m

Dec 31 2016US$4mUS$400k

-US$16m

報酬と市場: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD3.58M).

報酬と収益: Ron's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Ron Cooper (59 yo)

7.7yrs

在職期間

US$6,041,334

報酬

Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ronald H. Cooper
CEO, President & Director7.7yrsUS$6.04m0.16%
$ 1.5m
Simon Nicolas Harford
CFO & Treasurer4.4yrsUS$1.71m0.066%
$ 606.6k
Martha Carter
Chief Regulatory Officer6.3yrsUS$1.73m0.018%
$ 161.4k
Per-Goran Gillberg
Co-Founder & VP of Developmentno dataデータなしデータなし
Jan Mattsson
Chief Scientific Officer15.2yrsUS$1.40m0.17%
$ 1.6m
Joan Connolly
Chief Technology Officer1.9yrsデータなしデータなし
Jason Duncan
Chief Legal Officer4.8yrsデータなし0.016%
$ 145.5k
Michelle Graham
Chief Human Resources Officer3.3yrsデータなし0.027%
$ 244.7k
Kristina Torfgard
VP & Global Project Headno dataデータなしデータなし
Pamela Stephenson
Chief Commercial Officer4yrsUS$1.96m0.11%
$ 982.0k
Constantine Chinoporos
Chief Business Officer1.3yrsデータなしデータなし
Paul Streck
Chief Medical Officerless than a yearデータなしデータなし

4.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: ALBO's management team is considered experienced (4.2 years average tenure).

取締役

名称ポジション在職期間報酬所有権
Ronald H. Cooper
CEO, President & Director7.5yrsUS$6.04m0.16%
$ 1.5m
David Chiswell
Independent Chairman of the Board15.1yrsUS$282.44k0.27%
$ 2.5m
Davey Scoon
Independent Director6.3yrsUS$266.82k0.14%
$ 1.3m
Michael Gutch
Independent Director7.4yrsUS$264.94k0.13%
$ 1.2m
Craig Hopkinson
Directorless than a yearデータなしデータなし
Habib Dable
Independent Directorless than a yearデータなしデータなし
Stephanie Okey
Independent Director4.8yrsUS$249.94k0.14%
$ 1.3m
Susan Alesina
Directorless than a yearデータなしデータなし

5.5yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: ALBO's board of directors are considered experienced (5.5 years average tenure).